After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The group could soon provide clarity on CTX112’s regulatory path.
The THIO-104 study listing is live, along with questions about funding the trial.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
